Miglustat G.L. contains the active substance miglustat, which belongs to a group of medicines that affects metabolism. It is used to treat two diseases:
In Gaucher disease type 1, a substance called glucosylceramide is not removed from your body. It accumulates in certain cells in your immune system. This can lead to enlargement of the liver and spleen, blood changes, and bone disease.
The usual treatment for Gaucher disease type 1 is enzyme replacement therapy. Miglustat G.L. is used only in patients for whom enzyme replacement therapy is not an option.
If you have Niemann-Pick disease type C, fats, such as glycosphingolipids, accumulate in the cells of your brain. This can lead to disturbances in neurological functions such as slow eye movements, balance, swallowing, and memory, as well as seizures.
The active principle of Miglustat G.L. is the inhibition of an enzyme called “glucosylceramide synthase”. It is responsible for the first step in the synthesis of most glycosphingolipids.
| Strength | Pack size |
| 100 mg | 84 |
We ask for your understanding that due to the Austrian Medicines Act, certain further information is only accessible to medical professionals.
Login
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information